Affitech appoints cfo
Stig Jarle Pettersen was formerly a consultant to the Danish antibody medicines firm
Pettersen will be a member of the executive management of Affitech with managing director Martin Welschof and chief scientific officer Alexander Duncan.
Pettersen is a Norwegian state authorised public accountant with more than 20 years of experience at Hafslund Nycomed, Helicopter Services Group, Alpharma, Actavis and most recently as chief financial officer at Xellia Pharmaceuticals.
Pettersen worked as a consultant for Affitech in September 2009 and participated in the process of restructuring and refinancing the company. He now joins the company when, due to investment by TransNova in April, it is able to finance the further development of its two leading drug candidates in collaboration with NTSPlus of Russia.
Affitech expects to file a Clinical Trial Application in 2011 for its anti-VEGF antibody AT001/r84, whose main indication is for anti-angiogenesis treatment in several cancers.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing
As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Research & Development
VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development
The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies